Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eBlsCduTtWCjleeyCidyqVCicNDaNJ
| Today's Top Story |  |  | | | Health Care & Policy | | | | - Pfizer's Prevenar 13 vaccine wins expanded EU nod
The European Commission approved the use of Pfizer's antibacterial vaccine Prevenar 13 in patients ages 18 to 49. The vaccine provides protection against illnesses caused by 13 strains of Streptococcus pneumoniae. Prevenar 13 is already cleared for infants and children in more than 120 nations, and for adults 50 and older in 80-plus nations. Reuters (7/10)       | Company & Financial News | | | | - J&J joins $10.6M round for developer of stem cell treatment
Stem cell startup ViaCyte secured $10.6 million in a private equity funding round in which Johnson & Johnson, the Johnson Trust and Sanderling Ventures participated. The funding matches the $10.1 million grant approved last year by the California Institute for Regenerative Medicine to support clinical trials of ViaCyte's encapsulated cell therapy product, VC-01, for treatment of type 1 and insulin-dependent type 2 diabetes. Xconomy/San Diego (7/10) | Industry Deals | | | | - Sorrento signs option, license deal for anti-HCV antibodies
Sorrento Therapeutics and B.G. Negev Technologies and Applications, the technology transfer firm of Ben-Gurion University of the Negev, will work together to develop anti-hepatitis C virus antibodies. The collaboration will center on multiple fully human anti-HCV antibody clones identified by Ben-Gurion University professor Leslie Lobel in patients who recovered from HCV. "We are pleased to be collaborating with Sorrento to develop our fully human anti-HCV antibody clones into potential anti-HCV therapeutics," Lobel said. Vaccine News Daily (7/10) | Food & Agriculture | | | | - Research pioneer Beachy weighs in on state of biotech food
 Roger Beachy, Global Institute for Food Security CEO and pioneering biotech agriculture researcher, says genetic tools can reduce the use of chemicals in farming. Obstacles include health fears unsupported by years of scientific studies and a burdensome regulatory process that leaves universities and small developers unable to participate as fully as they used to. FoodNavigator (7/8) | Industrial & Environmental | | | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Join us Nov. 11-13 at the BIO Convention in China in Beijing!
The BIO Convention in China brings together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. Learn more and register today.
| SmartQuote | | | |  | Genius ... is the capacity to see ten things where the ordinary man sees one."
--Ezra Pound,
American expatriate poet and critic  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, July 10, 2013
- Tuesday, July 09, 2013
- Monday, July 08, 2013
- Friday, July 05, 2013
- Wednesday, July 03, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment